- Investing Ideas
- /
- Taiwanese Pharmaceuticals & Biotech High Return On Equity, Low Debt
Taiwanese Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
2
0 new
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
2 companies
Ever Supreme Bio Technology
Market Cap: NT$13.6b
Engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan.
6712
NT$155.50
7D
-0.6%
1Y
-11.1%
PharmaEngine
Market Cap: NT$11.7b
A biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan.
4162
NT$81.10
7D
-5.1%
1Y
-14.9%